

RESEARCH MONOGRAPH . COMPOUND PROFILE

Mirabegron

A selective beta-3 adrenoceptor agonist developed by Astellas Pharma as the first non-antimuscarinic oral treatment for overactive bladder, distinguished from the antimuscarinic drug class by its distinct receptor mechanism, favorable dry mouth and cognitive side-effect profile, moderate CYP2D6 inhibitory activity, and emerging research interest in brown adipose tissue thermogenesis, metabolic disease, and oncology.

DOCUMENT	KDC-MN-1532
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Selective beta-3 adrenergic receptor agonist with secondary CYP2D6 inhibitory activity

ABSTRACT

Mirabegron (YM-178) is a selective beta-3 adrenergic receptor (beta-3-AR) agonist approved in over 40 countries for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Developed by Astellas Pharma and first approved in Japan in 2011 and by the United States Food and Drug Administration in June 2012, mirabegron represented a paradigm shift in OAB pharmacotherapy as the first non-antimuscarinic agent approved for the indication, offering clinically meaningful efficacy with a substantially lower incidence of the dry mouth, constipation, and cognitive impairment that limit long-term adherence to antimuscarinic agents such as oxybutynin, tolterodine, solifenacin, darifenacin, and fesoterodine. The compound activates beta-3 adrenergic receptors on detrusor smooth muscle cells, producing cyclic adenosine monophosphate (cAMP)-mediated relaxation of the bladder wall during the storage phase and thereby increasing functional bladder capacity without impairing voiding contractility. At clinically approved doses (25 mg and 50 mg extended-release tablets administered once daily), mirabegron demonstrates high selectivity for the beta-3-AR over beta-1 and beta-2 adrenergic receptor subtypes, although modest beta-1-AR activity at supratherapeutic concentrations has been characterized and contributes to the dose-dependent cardiovascular signal (small increases in heart rate and blood pressure) that is the principal safety consideration in clinical use. The compound is also a moderate inhibitor of cytochrome P450 2D6 (CYP2D6), producing clinically relevant increases in systemic exposure to CYP2D6 substrates including metoprolol,

desipramine, and thioridazine, a property that requires attention in polypharmacy contexts. Four pivotal Phase 3 randomized controlled trials (SCORPIO, ARIES, CAPRICORN, and DRAGON) enrolling over 4,500 patients established the efficacy and tolerability of mirabegron at 25 mg and 50 mg doses, demonstrating statistically significant reductions in mean daily micturition frequency and incontinence episodes compared to placebo over 12-week treatment periods, with efficacy sustained through 12-month extension studies. The safety profile in pooled clinical trial data and in extensive postmarketing surveillance confirms a low incidence of dry mouth (comparable to placebo), with the principal treatment-emergent adverse events being hypertension (7 to 11 percent), nasopharyngitis, urinary tract infection, and headache. Cardiovascular safety analyses, including a multinational non-interventional cohort study, have not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators. Beyond the established OAB indication, mirabegron has attracted substantial research interest as a pharmacological activator of brown adipose tissue (BAT) thermogenesis through beta-3-AR-mediated stimulation of uncoupling protein 1 (UCP1) expression. Chronic mirabegron treatment in human subjects has been shown to increase BAT metabolic activity, resting energy expenditure, high-density lipoprotein cholesterol, adiponectin, and insulin sensitivity, positioning the compound as a research tool for metabolic disease and obesity pharmacology. Additional preclinical research has demonstrated antitumor activity through adipose tissue browning and modulation of the tumor microenvironment. This monograph reviews the chemistry, synthesis, and receptor pharmacology of mirabegron; the comprehensive human pharmacokinetic record including CYP2D6 inhibition; the clinical evidence base across

OAB and emerging metabolic indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; and a comparative assessment of five OAB pharmacotherapies against mirabegron on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Mirabegron.

Marketed names: Myrbetriq (Astellas Pharma; United States, Canada, European Union member states, and other jurisdictions), Betmiga (Astellas; United Kingdom, Australia, and selected European and Asian markets), Betanis (Astellas; Japan).

Development codes: YM-178 (Astellas Pharma). The development code is the canonical identifier in the early pharmacology and medicinal chemistry literature and is the identifier under which the initial beta-3-AR agonist characterization and dose-finding studies were conducted [1].

Chemical Abstracts Service registry number: 223673-61-8 (free base).

International Union of Pure and Applied Chemistry name: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-[(2R)-2-hydroxy-2-phenylethyl]amino)ethyl]phenyl]acetamide. The compound is a synthetic phenylethylamine derivative incorporating a 2-aminothiazole moiety linked through an acetamide bridge to a para-substituted aniline bearing a chiral (R)-2-hydroxy-2-phenylethylamino side chain.

1.2 Structural class and chemistry

Mirabegron is a synthetic arylacetamide-type beta-3 adrenergic receptor agonist. The structural class places it within the broader family of phenylethanolamine adrenergic ligands, though the presence of the 2-aminothiazole ring system distinguishes mirabegron from earlier beta-3-AR agonist scaffolds (such as the triaryl series and the indole-based series) and confers the selectivity profile that enabled clinical development [2].

Molecular formula: C₂₁H₂₄N₄O₂S (free base).

Exact mass: 396.1620 g/mol (free base, monoisotopic).

Molecular weight: 396.51 g/mol (free base).

Physical properties: White to off-white crystalline powder. The compound has low aqueous solubility that is pH-dependent (more soluble in acidic media). It is formulated as an extended-release (ER) tablet using an oral controlled absorption system (OCAS) to provide once-daily dosing pharmacokinetics. Melting point is approximately 137 to 141 degrees Celsius [3].

Stereochemistry: Mirabegron contains one stereocenter at the 2-position of the hydroxy-phenylethylamino side chain and is supplied as the single (R)-enantiomer. The (R)-configuration is critical for beta-3-AR agonist activity; the (S)-enantiomer shows substantially reduced receptor affinity in binding assays. Investigators acquiring research-grade mirabegron should confirm enantiomeric purity by chiral high-performance liquid chromatography or by polarimetry against a reference standard.

1.3 Synthesis

The published synthesis of mirabegron proceeds through convergent assembly of two principal fragments: the 2-aminothiazolylacetic acid component and the para-aminophenylethylamine bearing the chiral (R)-2-hydroxy-2-phenylethylamino substituent. The key steps involve: (a) Hantzsch thiazole synthesis to construct the 2-aminothiazole ring from an alpha-haloketone and thiourea; (b) preparation of the chiral amino alcohol fragment through asymmetric reduction or resolution of the corresponding ketone precursor to establish the (R)-stereocenter; (c) reductive amination or nucleophilic substitution to attach the amino alcohol to the 4-aminophenylethylamine linker; and (d) amide bond formation between the thiazolylacetic acid and the aniline nitrogen using standard peptide coupling reagents (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 1-hydroxybenzotriazole) or acid chloride activation [1, 4]. The product is purified by recrystallization and characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, and high-performance liquid chromatography. Industrial syntheses optimize the coupling step for yield and enantiomeric integrity; the compound is manufactured in high optical purity (greater than 99 percent enantiomeric excess).

2. Abstract

Mirabegron (YM-178) is a selective agonist of the beta-3 adrenergic receptor (beta-3-AR), the predominant adrenergic receptor subtype expressed on human detrusor smooth muscle, and the first non-antimuscarinic agent approved for the treatment of overactive bladder (OAB). The compound was discovered and developed by Astellas Pharma through a medicinal chemistry program that optimized selectivity for the human beta-3-AR over the beta-1 and beta-2 subtypes, oral bioavailability, and extended-release formulation characteristics suitable for once-daily dosing [1, 2].

The principal clinical application is the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency at oral doses of 25 mg or 50 mg once daily in an extended-release formulation. Four pivotal Phase 3 trials (SCORPIO, ARIES, CAPRICORN, and DRAGON) enrolling over 4,500 patients demonstrated statistically significant and clinically meaningful reductions in micturition frequency and incontinence episodes compared to placebo, with efficacy comparable to the antimuscarinic comparator tolterodine ER 4 mg but with substantially lower rates of dry mouth [5, 6, 7, 8]. Long-term safety and efficacy have been confirmed in 12-month extension studies enrolling over 2,400 patients.

The pharmacological distinction from the antimuscarinic class is clinically important. Antimuscarinic agents (oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium) produce bladder relaxation through blockade of muscarinic M2 and M3 receptors on detrusor smooth muscle, but the same receptor blockade in salivary glands, gastrointestinal smooth muscle, and the central nervous system produces dry mouth (incidence 20 to 60 percent depending on agent and dose), constipation, and, for agents crossing the blood-brain barrier, cognitive impairment in elderly patients. Mirabegron produces bladder relaxation through a distinct beta-3-AR-mediated pathway that does not involve muscarinic receptor blockade, resulting in dry mouth rates comparable to placebo (2 to 3 percent) and no demonstrable central anticholinergic effect [5, 6].

Beyond OAB, mirabegron has emerged as a pharmacological research tool for the study of beta-3-AR-mediated brown adipose tissue (BAT) thermogenesis in humans. Cypess et al. (2015) demonstrated acute activation of human BAT by a single

200 mg oral dose of mirabegron in healthy young men [9]. O'Mara et al. (2020) extended these findings to chronic dosing, reporting that 4 weeks of mirabegron 100 mg daily in healthy women increased BAT metabolic activity, resting energy expenditure, HDL cholesterol, adiponectin, and insulin sensitivity [10]. These metabolic findings, combined with preclinical data demonstrating antitumor effects through adipose tissue browning [11], position mirabegron as a compound of expanding research interest well beyond its urological origin.

The compound is metabolized by multiple hepatic pathways including CYP3A4, CYP2D6, butylcholinesterase, and uridine diphospho-glucuronosyltransferases (UGTs). Mirabegron is a moderate inhibitor of CYP2D6, producing clinically relevant increases in systemic exposure to CYP2D6 substrates (approximately 1.8- to 3.4-fold increases in C_{max} and AUC for metoprolol and desipramine at supratherapeutic doses) [12, 13]. This interaction requires dose adjustment or monitoring when mirabegron is co-administered with narrow therapeutic index CYP2D6 substrates.

The compound is well tolerated at approved doses. The principal treatment-emergent adverse events are hypertension (7 to 11 percent), nasopharyngitis (3 to 4 percent), urinary tract infection (3 to 4 percent), and headache (2 to 3 percent). Cardiovascular safety in pooled clinical trial data and in a large multinational non-interventional cohort study has not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators [14, 15].

3. Discovery and Development History

3.1 Origin

The discovery of mirabegron arose from research at Yamanouchi Pharmaceutical (which merged with Fujisawa Pharmaceutical in 2005 to form Astellas Pharma) aimed at identifying selective beta-3 adrenergic receptor agonists for urological applications. The beta-3-AR had been identified in the 1980s as the predominant adrenergic receptor subtype in human detrusor smooth muscle, and pharmacological studies in the 1990s established that beta-3-AR agonism could produce bladder relaxation during the storage phase without impairing voiding contraction [1, 16]. Earlier beta-3-AR agonist programs (BRL-37344, CL-316,243, and related compounds) had demonstrated preclinical efficacy in bladder models but lacked the species selectivity, oral bioavailability, or safety profiles required for human clinical development.

The Yamanouchi medicinal chemistry team systematically explored arylacetamide and arylsulfonamide scaffolds bearing 2-aminothiazole and phenylethanolamine pharmacophores. Mirabegron (YM-178) was selected from this series on the basis of high intrinsic activity at the human beta-3-AR (EC₅₀ approximately 22 nM), selectivity over beta-1 and beta-2 receptors (selectivity ratio greater than 100-fold at therapeutic concentrations), oral bioavailability in multiple species, and a tolerability profile in preclinical toxicology studies that supported clinical advancement [1].

3.2 Clinical development and registration

Mirabegron entered Phase 1 clinical studies in the early 2000s, with dose-finding and pharmacokinetic characterization in healthy volunteers establishing the extended-release formulation and the 25 mg to 100 mg dose range. Phase 2 dose-ranging studies in OAB patients identified 50 mg as the optimal dose balancing efficacy and tolerability.

The Phase 3 clinical program comprised four multinational randomized double-blind placebo-controlled trials conducted between 2007 and 2010:

The DRAGON study (Phase 2b/3, conducted in Europe) evaluated mirabegron at 25 mg, 50 mg, 100 mg, and 200 mg versus placebo over 12 weeks and established the dose-response relationship, confirming 50 mg as the optimal clinical dose [8].

The SCORPIO trial (n = 1,978; Europe, Australia, South Africa) compared mirabegron 50 mg and 100 mg with tolterodine ER 4 mg and placebo over 12 weeks [5]. Both mirabegron doses produced statistically significant reductions in mean daily micturitions and incontinence episodes versus placebo, with efficacy comparable to tolterodine and dry mouth rates similar to placebo.

The ARIES trial (n = 1,329; United States, Canada) compared mirabegron 50 mg and 100 mg with placebo over 12 weeks without an active comparator [6]. Both doses demonstrated statistically significant improvements on all primary and key secondary endpoints.

The CAPRICORN trial (n = 1,306; Europe, Australia) compared mirabegron 25 mg and 50 mg with placebo over 12 weeks and was the principal trial supporting the 25 mg dose indication [7].

Mirabegron received its first regulatory approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in July 2011 and was launched as Betanis in September 2011. The United States Food and Drug Administration approved mirabegron (Myrbetriq) in June 2012 as the first beta-3-AR agonist for OAB. The European Medicines Agency granted marketing authorization in December 2012 (Betmiga). As of the most recent monograph revision, mirabegron is approved in over 40 countries and is marketed in North America, Europe, Japan, Australia, and selected markets in Asia, Latin America, and the Middle East.

3.3 Expansion to pediatric and combination indications

In 2021, the FDA approved an expanded indication for mirabegron as an extended-release oral suspension for pediatric patients aged 3 years and older with neurogenic detrusor overactivity. The SYNERGY and BESIDE Phase 3 trials evaluated mirabegron in combination with solifenacin for OAB patients with inadequate response to monotherapy, supporting the clinical rationale for dual-mechanism combination therapy [17].

3.4 Identification of metabolic research applications

Beginning in 2012, the Cypess laboratory at the National Institutes of Health and subsequently multiple independent groups identified mirabegron as a pharmacological activator of human brown adipose tissue through its beta-3-AR agonist mechanism [9]. The identification of this metabolic application, though outside the registered indication, has generated a substantial and growing research literature on beta-3-AR agonism as a therapeutic strategy for obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome.

4. Mechanism of Action

Mirabegron is a selective agonist of the beta-3 adrenergic receptor. Its principal molecular activity, characterized in heterologous expression systems and confirmed in native tissue preparations and in vivo, is activation of the beta-3-AR on detrusor smooth muscle and on brown adipocytes. A secondary pharmacological activity of clinical importance is moderate inhibition of cytochrome P450 2D6 (CYP2D6).

4.1 Beta-3 adrenergic receptor agonism in the bladder

The beta-3 adrenergic receptor is a G-protein-coupled receptor of the beta-adrenergic subfamily, encoded by the ADRB3 gene. In human detrusor smooth muscle, the beta-3-AR is the predominant adrenergic receptor subtype, accounting for approximately 97 percent of total beta-adrenergic receptor mRNA expression [16]. The receptor couples to Gs alpha subunits and activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets including myosin light chain kinase (reducing contractile tone), large-conductance calcium-activated potassium channels (BKCa channels, producing membrane hyperpolarization), and phospholamban (reducing intracellular calcium availability). The integrated functional consequence is smooth muscle relaxation during the bladder storage phase [16, 18].

Mirabegron activates the human beta-3-AR with an EC₅₀ of approximately 22 nanomolar in recombinant cell systems and an intrinsic activity of approximately 0.66 relative to the full agonist isoproterenol. The compound therefore behaves as a partial agonist at the recombinant receptor, though in native detrusor tissue the effective relaxation response is functionally near-complete owing to receptor reserve [19]. Selectivity for the human beta-3-AR over the beta-1-AR and beta-2-AR is greater than 100-fold at concentrations achieved by the approved 50 mg oral dose, with minimal intrinsic activity at the beta-1 and beta-2 subtypes at therapeutic plasma concentrations.

The bladder relaxation mechanism is fundamentally distinct from the antimuscarinic mechanism. Antimuscarinic agents block muscarinic M2 and M3 receptors on detrusor smooth muscle to reduce parasympathetic-mediated contraction.

Mirabegron instead promotes sympathetically mediated relaxation through the beta-3-AR pathway, operating through a separate arm of autonomic neuropharmacology. This mechanistic separation is the basis for the absence of antimuscarinic side effects (dry mouth, constipation, cognitive impairment) and is the principal pharmacological rationale for the development of the beta-3-AR agonist class [18].

An additional proposed mechanism involves inhibition of sensory afferent nerve activity in the bladder wall. Beta-3-AR agonism may reduce the firing of C-fiber and A-delta mechanoreceptors in the suburothelium, reducing urgency signaling to the micturition center in the pontine tegmentum. This afferent mechanism, supported by animal electrophysiology studies, may contribute to the reduction in urgency symptoms observed in clinical trials independently of the detrusor relaxation effect [20].

4.2 Beta-3 adrenergic receptor agonism in brown adipose tissue

The beta-3-AR is highly expressed on brown adipocytes, where it mediates the thermogenic response to sympathetic nervous system activation. Beta-3-AR agonism on brown adipocytes increases cAMP, activates PKA, and triggers a signaling cascade that culminates in lipolysis and activation of uncoupling protein 1 (UCP1) in the inner mitochondrial membrane. UCP1 dissipates the proton gradient generated by the electron transport chain as heat rather than ATP, constituting the molecular basis of non-shivering thermogenesis [21].

Mirabegron activates this pathway in human brown adipocytes and in vivo in human subjects. Cypess et al. (2015) demonstrated that a single 200 mg oral dose of mirabegron in healthy young men produced measurable increases in BAT metabolic activity (quantified by 18F-fluorodeoxyglucose positron emission tomography) and in resting energy expenditure [9]. O'Mara et al. (2020) demonstrated that chronic mirabegron treatment (100 mg daily for 4 weeks) in healthy young women increased BAT activity, resting energy expenditure, plasma HDL cholesterol, adiponectin, and insulin sensitivity, and produced a shift in adipose tissue phenotype toward beige/brown characteristics in subcutaneous white adipose tissue biopsy specimens [10]. These findings have established mirabegron as the principal pharmacological tool for the study of beta-3-AR-mediated BAT thermogenesis in humans.

The metabolic research doses (100 to 200 mg) are higher than the approved OAB doses (25 to 50 mg), and the cardiovascular effects (increased heart rate and blood pressure) at these supratherapeutic doses may limit clinical translation for metabolic indications. Whether lower doses produce clinically meaningful metabolic effects without cardiovascular risk is an active area of investigation.

4.3 Beta-1 adrenergic receptor activity at supratherapeutic concentrations

At plasma concentrations exceeding those achieved by the approved 50 mg dose, mirabegron demonstrates measurable agonist activity at the beta-1-AR. Sazandeh et al. (2017) characterized this activity in human atrial tissue, reporting that mirabegron-induced increases in atrial contractile force in isolated human atrial appendages are mediated predominantly through beta-1-AR rather than beta-3-AR activation [22]. This off-target beta-1-AR activity at higher concentrations is the molecular basis for the dose-dependent increases in heart rate and blood pressure observed in clinical studies and contributes to the cardiovascular safety signal at supratherapeutic doses.

4.4 CYP2D6 inhibition

Mirabegron is a moderate inhibitor of CYP2D6 through a mechanism-based (time-dependent) inhibition pathway. The clinical consequence is increased systemic exposure to CYP2D6 substrates when co-administered with mirabegron. At the approved 50 mg dose, the magnitude of CYP2D6 inhibition is clinically relevant for narrow therapeutic index substrates; at higher research doses, the inhibition is proportionally greater [12, 13].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Mirabegron is administered orally as an extended-release tablet. Absorption after oral dosing is moderate, with absolute bioavailability of approximately 29 percent at the 25 mg dose and approximately 35 percent at the 50 mg dose, increasing to approximately 45 percent at 150 mg [23]. The more-than-dose-proportional increase in bioavailability at higher doses is attributed to saturation of intestinal P-glycoprotein efflux transport. Time to peak plasma concentration (T_{max}) is approximately 3 to 5 hours after oral administration. Food does not have a clinically significant effect on overall mirabegron exposure (AUC), though it modestly reduces C_{max} by approximately 45 percent for the 50 mg tablet. The FDA-approved label permits administration with or without food.

Steady-state plasma concentrations are achieved within approximately 7 days of once-daily dosing. At steady state, the mean maximum plasma concentration (C_{max}) after 50 mg once daily is approximately 61 ng/mL and the mean 24-hour AUC is approximately 1,100 ng per hour per mL [23].

5.2 Distribution

Mirabegron has a large volume of distribution (approximately 1,670 liters), reflecting extensive tissue partitioning. Plasma protein binding is approximately 71 percent, primarily to albumin and alpha-1-acid glycoprotein. The compound distributes to peripheral tissues including bladder, adipose tissue, and skeletal muscle. Central nervous system penetration is limited; the compound is a substrate of P-glycoprotein efflux transporters at the blood-brain barrier, and the absence of demonstrable central anticholinergic cognitive effects in clinical studies is consistent with limited brain exposure [24].

5.3 Metabolism

Mirabegron is metabolized in the liver through multiple parallel pathways. The major metabolic routes include: (a) dealkylation by CYP3A4, producing the des-isopropyl metabolite; (b) oxidation by CYP2D6; (c) amide hydrolysis by butylcholinesterase; and (d) direct glucuronidation by UGT enzymes. No single metabolic pathway dominates overall elimination, and the contribution of any individual CYP isoform to total clearance is limited. The principal circulating metabolites are pharmacologically inactive at the beta-3-AR [13, 24].

The role of CYP2D6 in mirabegron metabolism is limited. In vivo studies comparing CYP2D6 extensive metabolizers and poor metabolizers have shown that the effect of CYP2D6 phenotype on mirabegron exposure is small (approximately 20 percent increase in AUC in poor metabolizers) and likely of limited clinical importance for mirabegron dosing [13]. This contrasts with the clinically significant CYP2D6 inhibition that mirabegron exerts on other CYP2D6 substrates.

5.4 Elimination

The terminal elimination half-life of mirabegron is approximately 50 hours, which is long relative to the 24-hour dosing interval and supports once-daily administration. Total body clearance is approximately 57 liters per hour. Elimination is through both renal and hepatic routes: approximately 55 percent of an administered dose is recovered in urine (25 percent as unchanged drug) and approximately 34 percent in feces (0.5 percent unchanged) [23, 24]. The substantial renal excretion of unchanged drug suggests a component of active renal secretion.

Dose adjustment is recommended in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²; maximum dose 25 mg daily) and in patients with moderate hepatic impairment (Child-Pugh class B; maximum dose 25 mg daily). Mirabegron has not been studied and is not recommended in patients with end-stage renal disease or severe hepatic impairment (Child-Pugh class C).

5.5 Routes of administration

The approved route of administration is oral, as an extended-release tablet (25 mg, 50 mg) or as an extended-release oral suspension (pediatric formulation). The extended-release formulation uses an oral controlled absorption system (OCAS) to provide sustained drug release over the gastrointestinal transit period. The tablets

should be swallowed whole; crushing or chewing may alter the release profile and increase peak plasma concentrations. Intravenous formulations have been used in pharmacokinetic characterization studies to determine absolute bioavailability but are not commercially available [23].

5.6 Special populations

Pediatric: Mirabegron is approved for neurogenic detrusor overactivity in patients aged 3 years and older. Pediatric dosing is weight-based using the extended-release oral suspension formulation. Pharmacokinetic modeling supports body-weight-adjusted doses that achieve exposures comparable to the adult 25 mg dose.

Geriatric: No dose adjustment is required based on age alone. In pooled clinical trial analyses, patients aged 65 years and older showed similar efficacy and tolerability to younger patients. Mirabegron does not produce the central anticholinergic effects that complicate antimuscarinic use in elderly populations, a clinically important advantage in the typical OAB patient demographic.

Pregnancy and lactation: Mirabegron is classified as pregnancy category C. Animal reproduction studies at doses producing exposures 22 times the human exposure at the maximum recommended human dose produced reversible adverse effects on fertility and offspring development. There are no adequate and well-controlled studies in pregnant women. Mirabegron is excreted in rat milk; human lactation data are limited. The compound should be used during pregnancy and lactation only if the potential benefit justifies the potential risk.

6. Preclinical Pharmacology

6.1 In vitro receptor pharmacology

In recombinant cell-based functional assays, mirabegron activates the human beta-3 adrenergic receptor with an EC₅₀ of approximately 22 nanomolar (cAMP accumulation endpoint), with no detectable agonist activity at human beta-1 or beta-2 receptors at concentrations up to 10 micromolar [1]. In isolated human detrusor smooth muscle strips, mirabegron produces concentration-dependent relaxation of carbachol-precontracted tissue, with an EC₅₀ consistent with the recombinant receptor data [16].

Species differences in beta-3 receptor pharmacology are noteworthy: mirabegron potency at the rat beta-3 receptor is approximately 10-fold lower than at the human receptor, necessitating higher doses in rat preclinical models to achieve pharmacologically equivalent receptor occupancy [1, 19].

6.2 In vivo bladder models

In conscious rat cystometry models, mirabegron (0.3 to 10 mg/kg oral) increased bladder capacity and intercontraction interval in a dose-dependent manner without affecting voiding pressure or residual volume, confirming the storage-phase selectivity of the mechanism [19]. In rat models of bladder outlet obstruction, mirabegron significantly reduced non-voiding contractions compared to untreated obstructed animals, with preservation of voiding efficiency [25]. In a chronic bladder ischemia model, oral mirabegron preserved bladder compliance and reduced ischemia-induced detrusor overactivity, suggesting a protective effect on bladder function beyond simple relaxation [26].

6.3 Metabolic and adipose tissue models

In murine brown adipose tissue, mirabegron activates UCP1-dependent thermogenesis and stimulates lipolysis. In diet-induced obese mice, chronic mirabegron administration reduces body weight gain, improves glucose tolerance, and increases energy expenditure [27]. Lv et al. (2023) demonstrated that mirabegron-induced

global browning of white adipose tissue produces anticancer effects in orthotopic mouse models of pancreatic ductal adenocarcinoma and hepatocellular carcinoma, with tumor volume reductions of 40 to 60 percent relative to vehicle-treated controls [11].

6.4 Cardiovascular preclinical models

In isolated guinea pig and rabbit atrial and ventricular preparations, mirabegron at concentrations exceeding 1 micromolar produces positive inotropic and chronotropic effects attributed to off-target beta-1 receptor activation rather than beta-3 receptor signaling [22]. In anesthetized dog models, intravenous mirabegron produces dose-dependent increases in heart rate and cardiac output at supratherapeutic exposures, with minimal cardiovascular effects at exposures corresponding to the approved 50 mg human dose [24].

7. Clinical Evidence Base

7.1 Overactive bladder: pivotal Phase 3 trials

SCORPIO (Study 178-CL-046): A 12-week, randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial enrolling 1,978 patients with OAB across 189 sites in Europe, Australia, and South Africa [5]. Patients were randomized to mirabegron 50 mg (n = 493), mirabegron 100 mg (n = 496), tolterodine ER 4 mg (n = 495), or placebo (n = 494) for 12 weeks. The co-primary endpoints were change from baseline to final visit in mean number of incontinence episodes per 24 hours and mean number of micturitions per 24 hours. Mirabegron 50 mg produced adjusted mean reductions of -1.57 incontinence episodes (placebo -1.17; $p < 0.05$) and -1.93 micturitions (placebo -1.34; $p < 0.001$) per 24 hours. Mirabegron 100 mg produced comparable reductions of -1.46 and -1.77, respectively. Dry mouth incidence was 2.8 percent for mirabegron 50 mg, 2.8 percent for mirabegron 100 mg, 2.6 percent for placebo, and 10.1 percent for tolterodine ER 4 mg.

ARIES (Study 178-CL-045): Conducted at 124 sites in the United States and Canada, this trial randomized 1,329 OAB patients to mirabegron 50 mg (n = 442), mirabegron 100 mg (n = 443), or placebo (n = 444) for 12 weeks without an active comparator [6]. Both mirabegron doses produced statistically significant improvements (p less than or equal to 0.05) on all primary and key secondary endpoints, including micturition frequency, incontinence episodes, urgency episodes, and voided volume per micturition.

CAPRICORN (Study 178-CL-047): Conducted in Europe and Australia, this trial randomized 1,306 OAB patients to mirabegron 25 mg (n = 433), mirabegron 50 mg (n = 440), or placebo (n = 433) for 12 weeks [7]. Both doses demonstrated statistically significant efficacy on the co-primary endpoints. This trial was the principal basis for the 25 mg dose in the approved label, providing the lower starting dose option for patients who may not require or may not tolerate the 50 mg dose.

DRAGON (Study 178-CL-044): This Phase 2b/3 dose-ranging study, conducted in Europe, evaluated mirabegron 25 mg, 50 mg, 100 mg, and 200 mg versus placebo over 12 weeks in 928 OAB patients [8]. The study established the dose-response rela-

tionship and confirmed that 50 mg provided optimal efficacy with acceptable tolerability. The 200 mg dose produced greater cardiovascular effects without proportional efficacy gains, informing the dose selection for the pivotal Phase 3 program.

7.2 Long-term efficacy and safety

Two 12-month extension studies enrolled patients completing the SCORPIO and ARIES trials on mirabegron 50 mg or 100 mg. A total of 2,444 patients received mirabegron for up to 12 months. Efficacy on micturition frequency and incontinence endpoints was sustained through 12 months. The safety profile was consistent with the 12-week pivotal data, with no new safety signals identified in long-term treatment [28]. Rates of study discontinuation due to adverse events were 6.4 percent for mirabegron 50 mg and 6.2 percent for mirabegron 100 mg.

7.3 Combination therapy

The SYNERGY and BESIDE trials evaluated the combination of mirabegron 25 mg or 50 mg with the antimuscarinic solifenacin 5 mg in OAB patients with inadequate response to antimuscarinic monotherapy [17]. The SYNERGY trial (n = 3,398) demonstrated that the combination of mirabegron 50 mg plus solifenacin 5 mg produced statistically significant improvements in incontinence episodes compared to solifenacin monotherapy or mirabegron monotherapy. The combination was well tolerated, with dry mouth rates intermediate between mirabegron monotherapy and solifenacin monotherapy.

7.4 Neurogenic detrusor overactivity

Mirabegron has been evaluated in patients with neurogenic detrusor overactivity (NDO) secondary to spinal cord injury, multiple sclerosis, and spina bifida. Phase 3 trials in pediatric NDO populations supported the expanded FDA indication in 2021. Efficacy endpoints (maximum cystometric capacity, number of incontinence episodes) showed improvement relative to placebo, with tolerability consistent with the adult OAB population [29].

7.5 Brown adipose tissue and metabolic effects

Acute BAT activation: Cypess et al. (2015) administered a single 200 mg oral dose of mirabegron to 12 healthy young men in a randomized double-blind placebo-controlled crossover study [9]. 18F-FDG PET/CT imaging demonstrated significantly increased BAT metabolic activity (measured as standardized uptake value) in the supraclavicular and paravertebral depots. Resting energy expenditure increased by approximately 203 kcal per day, and plasma free fatty acid concentrations increased, consistent with beta-3-AR-mediated lipolysis. Heart rate and systolic blood pressure were also increased at this supratherapeutic dose.

Chronic metabolic effects: O'Mara et al. (2020) administered mirabegron 100 mg daily for 4 weeks to 14 healthy young women in an open-label study [10]. Chronic treatment produced measurable increases in BAT metabolic activity on PET/CT, increased resting energy expenditure, and produced a constellation of metabolic improvements: HDL cholesterol increased, adiponectin increased by 35 percent, and an intravenous glucose tolerance test revealed improved insulin sensitivity and glucose effectiveness. Subcutaneous adipose tissue biopsies showed increased expression of UCP1 and other brown/beige adipocyte markers, indicating white-to-beige adipose tissue remodeling. Body weight and composition did not change over the 4-week study period.

Meta-analysis findings: A 2024 systematic review and meta-analysis of studies examining mirabegron effects on BAT and metabolism confirmed significant increases in BAT activity, resting energy expenditure, free fatty acids, body temperature, and heart rate [30]. The review concluded that mirabegron has potential as a BAT activator for metabolic research but noted that the cardiovascular effects at metabolically effective doses may limit clinical translation.

7.6 Oncology

Lv et al. (2023) reported that mirabegron displayed anticancer effects in preclinical tumor models through global browning of adipose tissue [11]. In tumor-bearing mice, mirabegron treatment reduced tumor growth and modified the tumor microenvironment through beta-3-AR-mediated effects on adipose tissue metabolism and immune cell function. These findings are preclinical and have not been evaluated in human clinical trials for oncology indications.

8. Sourcing and Quality Verification

Pharmaceutical-grade mirabegron (Myrbetriq brand or licensed generic) is the highest quality source for research applications where regulatory equivalence to clinical material is operationally important. The pharmaceutical-grade material is supplied as 25 mg and 50 mg extended-release tablets. Generic mirabegron tablets have become available in multiple jurisdictions following patent expiration.

Research-grade mirabegron is supplied by multiple chemical and pharmaceutical research suppliers (Cayman Chemical, Sigma-Aldrich/MilliporeSigma, MedChemExpress, Selleckchem, Santa Cruz Biotechnology, BOC Sciences, and others) at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as the free base; pricing is moderate, in the range of \$50 to \$300 per 100 milligrams of high-purity research material at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (397.17 for the protonated free base $[M+H]^+$)
- Chiral HPLC confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (R)-form, since the (S)-enantiomer shows substantially reduced beta-3-AR agonist activity)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation
- Karl Fischer or loss-on-drying analysis for residual water
- Residual solvent analysis (gas chromatography of common synthesis solvents: methanol, ethanol, dichloromethane, ethyl acetate, dimethylformamide)

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, and others) provide independent confirmation of vendor certificates of analysis. The research-grade mirabegron market is well established and counterfeit material is uncommon, but lot-to-lot variability is observed and on-receipt analytical confirmation is appropriate for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Mirabegron free base has limited aqueous solubility at neutral pH (less than 1 mg/mL). For in vitro research applications requiring dissolved compound, stock solutions are typically prepared in dimethyl sulfoxide (DMSO) at concentrations of 10 to 50 mM (approximately 4 to 20 mg/mL), with subsequent dilution into aqueous media for cell-based assays. Final DMSO concentrations in the assay should not exceed 0.1 to 0.5 percent to minimize solvent-related cytotoxicity.

For in vivo research in animal models, mirabegron has been formulated in: (a) 0.5 percent methylcellulose aqueous suspension for oral gavage; (b) polyethylene glycol 400 (PEG-400) and Tween 80 co-solvent systems for parenteral administration; and (c) acidified aqueous solutions (pH 2 to 3, using hydrochloric acid or citric acid) where pH-dependent solubility is exploited.

Solid mirabegron should be stored at room temperature (15 to 25 degrees Celsius) in a tightly sealed container protected from moisture. The compound is stable under standard storage conditions for the duration of its assigned shelf life (typically 2 to 3 years for research-grade material). Stock solutions in DMSO should be stored at minus 20 degrees Celsius and are stable for at least 6 months. Aqueous formulations should be prepared fresh or stored refrigerated (2 to 8 degrees Celsius) and used within 7 to 14 days.

Aliquoting of DMSO stock solutions into single-use volumes is recommended to avoid repeated freeze-thaw cycles; three or fewer freeze-thaw cycles are generally tolerable without measurable potency loss, but the compound should be retested by HPLC if more cycles are anticipated.

For clinical-research formulations, the pharmaceutical extended-release tablets should be swallowed whole and not crushed, chewed, or divided, as disruption of the extended-release mechanism may produce dose-dumping with transiently elevated peak plasma concentrations. The pediatric extended-release granule suspension (8 mg/mL after reconstitution in 100 mL water) is stable for 28 days at room temperature after reconstitution.

10. Stack Interactions and Combinations

Mirabegron interacts with several drug classes through its CYP2D6 inhibitory activity, its beta-adrenergic receptor pharmacology, and its renal and hepatic elimination pathways. Investigators conducting research with mirabegron, especially in chronic dosing regimens or in combination with other research compounds, should consider:

CYP2D6 substrates: Mirabegron is a moderate CYP2D6 inhibitor. Co-administration increases systemic exposure to CYP2D6 substrates. Clinically characterized interactions include: metoprolol (C_{max} increased 1.9-fold, AUC increased 3.3-fold at mirabegron 160 mg), desipramine (C_{max} increased 1.8-fold, AUC increased 3.4-fold at mirabegron 100 mg) [12]. Narrow therapeutic index CYP2D6 substrates requiring dose adjustment or avoidance include thioridazine, flecainide, and propafenone. Other CYP2D6 substrates that may require monitoring include codeine (reduced conversion to morphine), tamoxifen (reduced conversion to endoxifen), and atomoxetine.

Digoxin: Mirabegron increases digoxin C_{max} by 29 percent and AUC by 27 percent through inhibition of intestinal P-glycoprotein [24]. Digoxin levels should be monitored when initiating or adjusting mirabegron in patients on digoxin therapy.

Warfarin: Mirabegron had no clinically significant effect on warfarin pharmacokinetics or pharmacodynamics (INR, prothrombin time) in a dedicated interaction study [24].

Antimuscarinic agents: Combination of mirabegron with antimuscarinic OAB agents (solifenacin, tolterodine, fesoterodine) has been evaluated clinically and is generally well tolerated. Pharmacokinetic interactions are modest: mirabegron increases solifenacin exposure by approximately 1.2-fold through CYP3A4 modulation. The combination produces additive pharmacodynamic effects on bladder relaxation through complementary mechanisms [17].

Antihypertensive agents: The blood pressure-elevating effect of mirabegron (typically 1 to 2 mm Hg systolic at approved doses) may partially offset the effects of antihypertensive medications. Clinical significance at approved doses is generally limited, but monitoring is appropriate when initiating mirabegron in patients on antihypertensive therapy. The CYP2D6-mediated interaction with metoprolol increases beta-blocker exposure and may produce excessive bradycardia or hypotension if not monitored.

QT-prolonging agents: Mirabegron at supratherapeutic doses (200 mg) has produced small increases in QTc interval in thorough QT studies. Combination with other QT-prolonging agents should be approached with caution, particularly at research doses exceeding the approved 50 mg.

CYP3A4 inhibitors: Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) modestly increase mirabegron exposure (ketoconazole increased AUC by less than 2-fold), which is not considered clinically significant for most patients. However, the dose should not exceed 25 mg daily in patients with severe renal or moderate hepatic impairment who are concurrently receiving strong CYP3A4 inhibitors.

Other beta-3-AR agonists: Concurrent administration with vibegron is pharmacologically additive at the beta-3-AR and has not been clinically studied. The combination is not recommended in clinical practice.

11. Adverse Events and Safety Signal

11.1 Common adverse events

The principal treatment-emergent adverse events at approved doses, as characterized in pooled Phase 3 clinical trial data, are:

- Hypertension (7.5 to 11.3 percent at 25 or 50 mg, compared to 7.6 percent on placebo; dose-dependent; reflects modest beta-adrenergic cardiovascular activity)
- Nasopharyngitis (3.4 to 4.4 percent)
- Urinary tract infection (2.9 to 4.2 percent)
- Headache (2.0 to 3.3 percent)
- Constipation (1.6 to 2.0 percent; substantially lower than antimuscarinic comparators at 5 to 15 percent)
- Dry mouth (2.0 to 2.8 percent; comparable to placebo at 2.6 percent and substantially lower than tolterodine ER at 10.1 percent or oxybutynin at 30 to 60 percent)
- Tachycardia (1.2 to 1.5 percent at approved doses)
- Dizziness (1.0 to 1.5 percent)

These adverse-event rates are generally comparable to or lower than those of antimuscarinic comparators, with the notable advantage of substantially lower dry mouth and constipation rates. The hypertension signal is the principal distinguishing adverse effect relative to placebo.

11.2 Cardiovascular safety

The cardiovascular safety of mirabegron has been extensively characterized. At approved doses (25 and 50 mg), mean increases in supine systolic blood pressure of 0.5 to 1 mm Hg and in diastolic blood pressure of 0.5 to 1 mm Hg above placebo have been observed [14]. Heart rate increases of approximately 1 beat per minute above placebo have been reported at the 50 mg dose.

A thorough QT/QTc study at a supratherapeutic dose of 200 mg showed a mean increase of approximately 4 to 5 milliseconds in QTcF interval, which did not exceed the regulatory threshold of concern (10 milliseconds).

A multinational non-interventional cohort study (conducted in the United States, United Kingdom, France, and Canada using healthcare databases) compared cardiovascular event rates in mirabegron users versus antimuscarinic users and found no increased risk of major adverse cardiovascular events, acute myocardial infarction, stroke, cardiovascular mortality, or all-cause mortality in mirabegron users [15].

Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg). Periodic blood pressure monitoring is recommended in all patients, particularly in hypertensive patients.

At supratherapeutic doses used in metabolic research (100 to 200 mg), cardiovascular effects are more pronounced, including greater increases in heart rate (5 to 15 beats per minute), systolic blood pressure (5 to 15 mm Hg), and diastolic blood pressure (3 to 8 mm Hg) [9, 10]. These effects are attributed to loss of beta-3-AR selectivity and engagement of beta-1-AR at higher plasma concentrations.

11.3 Pharmacovigilance signals

Analysis of the FDA Adverse Event Reporting System (FAERS) database has identified elevated reporting odds ratios for atrial fibrillation, tachycardia, and arrhythmia in mirabegron-treated patients [31]. A Canadian population-based cohort study in adults aged 66 years and older did not identify a significantly increased risk of arrhythmia-related emergency department visits or hospitalizations with mirabegron relative to antimuscarinic agents [32]. The pharmacovigilance signal warrants continued monitoring but has not resulted in regulatory action or label modification beyond the existing blood pressure monitoring recommendation.

11.4 Urinary retention

Postmarketing surveillance has identified urinary retention as a potential adverse event, particularly in patients with bladder outlet obstruction or in males with benign prostatic hyperplasia. The incidence is rare at approved doses. Mirabegron

should be used with caution in patients with clinically significant bladder outlet obstruction [24].

11.5 Rare and serious adverse events

Postmarketing surveillance has identified rare serious adverse events:

- Angioedema of the face, lips, tongue, and/or larynx (rare; reported within hours to days of initial dosing)
- Severe hypertensive crisis in patients with pre-existing uncontrolled hypertension
- Stevens-Johnson syndrome and toxic epidermal necrolysis (extremely rare; individual case reports)
- Hepatic enzyme elevations (rare, generally clinically insignificant)

11.6 Pregnancy and lactation

Animal reproduction studies at exposures up to approximately 22 times the human exposure at 50 mg daily did not reveal teratogenicity. Human pregnancy data are insufficient to establish safety. Mirabegron is excreted in rat milk; human lactation data are limited. Use during pregnancy is not recommended unless the clinical benefit justifies the potential risk [24].

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five pharmacotherapeutic alternatives against mirabegron, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected to represent the principal pharmacological classes used in OAB treatment and the emerging beta-3-AR agonist class, with priority on compounds that have produced material clinical evidence and that address the same therapeutic context.

12.1 Vibegron (Gemtesa)

Mechanism: Selective beta-3 adrenergic receptor agonist. Vibegron demonstrates full agonist activity at the human beta-3-AR (intrinsic activity approximately 1.0 relative to isoproterenol) and higher selectivity for beta-3-AR over beta-1 and beta-2 subtypes than mirabegron [33].

Development trajectory: Developed by Kyorin Pharmaceutical (Japan) and licensed to Urovant Sciences (now Sumitovant Biopharma) for United States development. The EMPOWUR trial (n = 1,518) demonstrated significant efficacy on micturition frequency and incontinence endpoints versus placebo over 12 weeks [34]. Vibegron (Gemtesa) was approved by the FDA in December 2020 at a dose of 75 mg once daily.

Novelty: Low. The mechanism is the same beta-3-AR agonist class as mirabegron. The novelty is limited to the chemical entity and the pharmacokinetic profile.

Effect size: Comparable to mirabegron. The EMPOWUR trial reported reductions in micturition frequency and incontinence episodes of similar magnitude to those observed in the mirabegron Phase 3 program. Indirect treatment comparisons have not demonstrated statistically significant differences in efficacy between vibegron 75 mg and mirabegron 50 mg [35].

Promising potential: Moderate to high. Vibegron represents the second-generation beta-3-AR agonist with a potentially improved pharmacological profile (full agonist activity, no CYP2D6 inhibition). Active post-marketing surveillance and investigation in combination therapy and in special populations.

Side-effect profile: Favorable. Vibegron does not inhibit CYP2D6, eliminating the drug interaction liability that complicates mirabegron prescribing. Blood pressure effects in clinical trials were comparable to placebo (in contrast to the modest hypertension signal with mirabegron), potentially reflecting greater beta-3-AR selectivity. Dry mouth rates are comparable to placebo.

Overall validation: Moderate to high. Phase 3 efficacy and safety data supporting FDA approval, with a differentiated pharmacological profile.

Comparison to mirabegron: Vibegron has the advantages of full agonist activity, no CYP2D6 inhibition, and a potentially more favorable blood pressure profile. Mirabegron has the advantages of longer clinical experience (approved 2012 versus 2020), more extensive postmarketing safety data, availability in more jurisdictions, an established pediatric indication, and a research literature on BAT thermogenesis that has not been replicated with vibegron. For metabolic and BAT research, mirabegron remains the principal pharmacological tool.

12.2 Tolterodine (Detrol)

Mechanism: Non-selective antimuscarinic agent with moderate selectivity for bladder muscarinic M2 and M3 receptors over salivary gland muscarinic receptors. The extended-release (ER) formulation reduces peak plasma concentrations and attenuates some adverse effects relative to the immediate-release formulation [36].

Development trajectory: Developed by Pharmacia (now Pfizer) and approved by the FDA in 1998 (immediate-release) and 2001 (extended-release). Tolterodine ER 4 mg was the active comparator in the SCORPIO trial of mirabegron.

Novelty: Low. Tolterodine is a well-established antimuscarinic agent representing a mature drug class with over 25 years of clinical use.

Effect size: Moderate. In the SCORPIO trial, tolterodine ER 4 mg produced reductions in micturition frequency and incontinence episodes comparable to mirabegron 50 mg but with a dry mouth rate of 10.1 percent versus 2.8 percent for

mirabegron [5]. Long-term adherence to tolterodine is limited by antimuscarinic adverse effects.

Promising potential: Low. No significant further development expected. The compound is in extensive generic competition and is gradually being displaced by beta-3-AR agonists in clinical guidelines.

Side-effect profile: Moderate. Dry mouth (10 to 15 percent with the ER formulation), constipation (5 to 8 percent), blurred vision, dizziness, and the theoretical concern of central anticholinergic cognitive effects in elderly patients (though tolterodine has less CNS penetration than oxybutynin). No significant cardiovascular effects.

Overall validation: High. Extensive clinical trial evidence, decades of clinical experience, and well-characterized safety profile. However, the antimuscarinic adverse-effect burden remains a significant limitation.

Comparison to mirabegron: Tolterodine and mirabegron have comparable OAB efficacy. Mirabegron has the advantages of substantially lower dry mouth rates, no anticholinergic cognitive effects, and a distinct mechanism of action. Tolterodine has the advantages of lower cost (generic), longer clinical track record, and no blood pressure signal.

12.3 Solifenacin (Vesicare)

Mechanism: Selective muscarinic M3 receptor antagonist with relative selectivity for the M3 subtype over M2, M1, M4, and M5 subtypes [37].

Development trajectory: Developed by Astellas Pharma (the same sponsor as mirabegron) and approved by the FDA in 2004. Studied in combination with mirabegron in the SYNERGY and BESIDE trials.

Novelty: Low. Solifenacin represents an incremental advance within the antimuscarinic class through its M3 selectivity.

Effect size: Comparable to tolterodine and mirabegron on OAB efficacy endpoints. The M3 selectivity was expected to reduce dry mouth through sparing of salivary M1 receptors, but clinical dry mouth rates (10 to 27 percent depending on dose) remain substantially higher than mirabegron [37].

Promising potential: Moderate. Ongoing interest in combination with mirabegron for patients with inadequate monotherapy response. Otherwise, a mature compound in extensive generic competition.

Side-effect profile: Moderate. Dry mouth (10 to 27 percent at 5 to 10 mg), constipation (5 to 13 percent), blurred vision, urinary retention (particularly in males with BPH). QT prolongation has been reported at the 10 mg dose. Theoretical cognitive concern in elderly patients, though reduced relative to oxybutynin.

Overall validation: High. Extensive clinical trial and postmarketing data.

Comparison to mirabegron: Solifenacin has comparable OAB efficacy but higher rates of dry mouth, constipation, and potential cognitive effects. The combination of mirabegron plus solifenacin has demonstrated additive efficacy in Phase 3 trials [17], supporting a complementary relationship between the two mechanisms.

12.4 Oxybutynin (Ditropan)

Mechanism: Non-selective muscarinic receptor antagonist with direct smooth muscle relaxant properties and local anesthetic activity. Available in oral immediate-release, oral extended-release, topical gel, and transdermal patch formulations [38].

Development trajectory: Oxybutynin is the oldest antimuscarinic agent for OAB, first approved in the United States in 1975. It remains widely prescribed, particularly in generic oral formulations.

Novelty: Very low. Oxybutynin is the reference standard of the antimuscarinic class with over 50 years of clinical use.

Effect size: Moderate to high. Oxybutynin produces substantial reductions in micturition frequency and incontinence episodes, comparable to or slightly greater than newer antimuscarinics and beta-3-AR agonists on some endpoints. However, the high rates of antimuscarinic adverse effects substantially reduce long-term adherence and real-world effectiveness.

Promising potential: Low. No significant further development. Clinical guidelines increasingly recommend mirabegron or newer antimuscarinics as first-line therapy over oxybutynin, particularly in elderly patients, owing to the cognitive safety concern.

Side-effect profile: Poor relative to mirabegron. Dry mouth (30 to 60 percent for oral immediate-release), constipation (10 to 15 percent), blurred vision, cognitive impairment (particularly in elderly patients; oxybutynin crosses the blood-brain barrier readily and produces measurable central anticholinergic effects on cognitive testing). The 2019 Coupland et al. study in JAMA Internal Medicine reported an association between cumulative anticholinergic exposure (including oxybutynin) and increased dementia risk [39]. Topical and transdermal formulations reduce systemic exposure and attenuate some adverse effects.

Overall validation: High for efficacy; moderate for overall clinical positioning given the adverse-effect burden.

Comparison to mirabegron: Mirabegron offers a substantially improved tolerability profile relative to oral oxybutynin, with comparable or slightly lower OAB efficacy. The absence of anticholinergic cognitive effects is particularly important in the typical OAB patient demographic (elderly women). Oxybutynin retains a role as an inexpensive generic option and in topical/transdermal formulations where systemic exposure is minimized.

12.5 Onabotulinum toxin A (intravesical)

Mechanism: Inhibition of acetylcholine release from parasympathetic nerve terminals in the bladder wall through cleavage of SNARE complex proteins (specifically SNAP-25). The mechanism is fundamentally different from both the antimuscarinic and beta-3-AR agonist classes and involves direct neuromuscular junction blockade at the detrusor smooth muscle level [40].

Development trajectory: Allergan (now AbbVie) developed onabotulinum toxin A (Botox) for OAB and received FDA approval for the treatment of OAB in 2013. Administered as a cystoscopic intravesical injection of 100 units into the detrusor muscle at approximately 20 injection sites.

Novelty: High. The intravesical injection route and the neurotoxin mechanism represent a fundamentally different therapeutic approach from oral pharmacotherapy.

Effect size: High. Onabotulinum toxin A produces substantial reductions in urge incontinence episodes (approximately 50 to 70 percent reduction, with 20 to 30 percent of patients achieving complete continence). Effect duration is approximately 6

months per injection. Efficacy is generally considered greater than oral pharmacotherapy in treatment-refractory patients [40].

Promising potential: Moderate. The compound is established as a second- or third-line therapy for OAB refractory to oral pharmacotherapy. No significant further development expected in OAB; the treatment paradigm is mature.

Side-effect profile: Mixed. No systemic antimuscarinic or cardiovascular effects. The principal adverse events are procedure-related: urinary tract infection (15 to 20 percent), urinary retention requiring clean intermittent catheterization (5 to 8 percent), and dysuria. The need for cystoscopic administration under local or general anesthesia is a practical limitation.

Overall validation: High. Extensive clinical trial and real-world evidence supporting efficacy in refractory OAB. Established in clinical guidelines as a recommended therapy for patients who have failed or cannot tolerate oral pharmacotherapy.

Comparison to mirabegron: Onabotulinum toxin A and mirabegron occupy different positions in the OAB treatment algorithm. Mirabegron is a first-line oral therapy; onabotulinum toxin A is a second- or third-line interventional therapy. Direct comparison is limited by the different routes of administration, patient populations (refractory versus treatment-naïve), and outcome timeframes. Mirabegron has the advantages of oral administration, daily dosing flexibility, and a systemic metabolic research profile. Onabotulinum toxin A has the advantages of higher efficacy in refractory patients, 6-month duration of effect per administration, and absence of daily dosing requirements.

12.6 Comparator summary

The five comparators occupy distinct positions in the OAB treatment landscape and, for mirabegron, in the broader beta-3-AR pharmacology research space. **Vibegron** is the most pharmacologically similar comparator and represents a second-generation beta-3-AR agonist with full agonist activity, no CYP2D6 inhibition, and a potentially superior blood pressure profile. **Tolterodine** and **solifenacin** are antimuscarinic agents with comparable OAB efficacy but substantially higher rates of dry mouth, constipation, and potential cognitive effects. **Oxybutynin** is the oldest and least tolerable antimuscarinic agent, retained principally for its low cost.

Onabotulinum toxin A is a high-efficacy interventional option for treatment-refractory OAB that occupies a complementary rather than competitive position relative to mirabegron.

Mirabegron occupies a unique position in this comparator landscape: it was the first beta-3-AR agonist approved for OAB, has the most extensive clinical trial and postmarketing safety database in the class, has an established pediatric indication, and is the only compound with a substantial research literature on BAT thermogenesis and metabolic effects in humans. Its moderate CYP2D6 inhibitory activity is a clinically relevant limitation relative to vibegron, and its partial agonist activity at the beta-3-AR is a pharmacological limitation relative to vibegron's full agonist profile. For OAB clinical use, the choice between mirabegron and vibegron is informed by the drug interaction profile, the blood pressure profile, and clinical experience. For BAT and metabolic research, mirabegron remains the principal pharmacological tool with no established competitor.

The principal practical question for the research-clinical positioning of mirabegron is whether the supratherapeutic doses required for metabolic effects can be reconciled with the cardiovascular safety signal that escalates at those doses. The strength of the mirabegron metabolic research profile is the combination of a well-characterized clinical safety database at the approved 25 to 50 mg dose, a demonstrated BAT activation signal at 100 to 200 mg, and a growing literature on metabolic outcomes (HDL cholesterol, adiponectin, insulin sensitivity) that may ultimately inform the development of next-generation beta-3-AR agonists optimized for metabolic indications. The weakness is the current absence of a demonstrated metabolic effect at the approved dose, which limits near-term clinical translation for metabolic applications.

13. References

1. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. *J Pharmacol Exp Ther*. 2007;321(2):642-647.
2. Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. *Ther Adv Urol*. 2012;4(6):315-324.
3. PubChem. Mirabegron. Compound CID 9865528. National Center for Biotechnology Information. Accessed 2026.
4. World Intellectual Property Organization. WO2004/002481: Process for preparing phenylethanolamine derivatives. 2004.
5. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial (SCORPIO). *Eur Urol*. 2013;63(2):283-295.
6. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. *J Urol*. 2013;189(4):1388-1395.
7. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta3-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder (CAPRICORN). *Urology*. 2013;82(2):313-320.
8. Chapple CR, Dvivedi AK, Engelen B, et al. A phase 2b dose-ranging study of mirabegron in patients with overactive bladder. *Int Urogynecol J*. 2013;24(9):1447-1458.
9. Cypess AM, Weiner LS, Roberts-Toler C, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. *Cell Metab*. 2015;21(1):33-38.

10. O'Mara AE, Johnson JW, Linderman JD, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. *J Clin Invest.* 2020;130(5):2209-2219.
11. Lv Y, Zhang SY, Liang X, et al. Mirabegron displays anticancer effects by globally browning adipose tissues. *Nat Commun.* 2023;14(1):7610.
12. Krauwinkel W, Dickinson J, van Gelderen M, et al. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. *Eur J Drug Metab Pharmacokinet.* 2014;39(1):43-52.
13. Takusagawa S, Yajima K, Miyashita A, et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. *Clin Drug Investig.* 2013;33(6):429-440.
14. Nitti VW, Chapple CR, Engelen B, Blauwet MB, Huang M, Siddiqui E. Safety and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. *Int J Clin Pract.* 2014;68(8):972-985.
15. Chapple CR, Siddiqui E, Engkilde K, et al. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study. *Drug Saf.* 2021;44(10):1091-1106.
16. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. *Neurourol Urodyn.* 2007;26(6):752-756.
17. Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). *Eur Urol.* 2016;70(1):136-145.
18. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. *Physiol Rev.* 2004;84(3):935-986.
19. Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective beta3-adrenoceptor agonist mirabegron in rats. *Naunyn Schmiedeberg's Arch Pharmacol.* 2013;386(3):247-253.

20. Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. *Neurourol Urodyn*. 2010;29(5):771-776.
21. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. *Physiol Rev*. 2004;84(1):277-359.
22. Sazandeh M, Giles W, Engel M, et al. The beta3-adrenoceptor agonist mirabegron increases human atrial force through beta1-adrenoceptors: an indirect mechanism? *Br J Pharmacol*. 2017;174(16):2706-2715.
23. Iitsuka H, van Gelderen M, Tanaka Y, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder. *Int J Clin Pharmacol Ther*. 2015;53(1):72-81.
24. Myrbetriq (mirabegron) extended-release tablets. Prescribing Information. Astellas Pharma US, Inc. Revised 2018.
25. Sawada N, Nomiya M, Hood B, Andersson KE. The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction. *World J Urol*. 2020;38(7):1749-1756.
26. Nomiya M, Andersson KE, Yamaguchi O. Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. *Eur Urol*. 2014;65(5):870-878.
27. Cero C, Lea HJ, Zhu KY, Shamsi F, Tseng YH, Cypess AM. Beta3-adrenergic receptors regulate human brown/beige adipocyte thermogenesis via the beta3-AR-cAMP-UCP1 axis. *Cell Rep*. 2021;37(2):109840.
28. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*. 2013;63(2):296-305.
29. Blais AS, Bhatt N, et al. Beta-3 adrenergic agonist for the treatment of bladder dysfunction in children: a systematic review and meta-analysis. *J Urol*. 2022;207(6):1187-1197.
30. Xiang C, Gao Y, Zhang Y, et al. Effects of mirabegron on brown adipose tissue and metabolism in humans: a systematic review and meta-analysis. *Eur J Clin Pharmacol*. 2024;80(3):345-358.

31. Li Y, Zhang J, Wang Z, et al. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. *Front Pharmacol*. 2024;15:1376535.
32. Gomes T, Juurlink DN, Ho JM, et al. Association of mirabegron with the risk of arrhythmia in adult patients 66 years or older: a population-based cohort study. *JAMA Intern Med*. 2019;179(10):1432-1434.
33. Edmondson SD, Zhu C, Kar NF, et al. Vibegron shows high selectivity and potent agonist activity for beta3-adrenoceptors, irrespective of receptor density. *PLoS One*. 2023;18(8):e0290685.
34. Staskin D, Frankel J, Varano S, et al. International phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. *J Urol*. 2020;204(2):316-324.
35. Blossom J, Guthrie R, Engel SS, et al. Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison. *Adv Ther*. 2021;38(11):5452-5464.
36. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. *Br J Urol*. 1998;81(6):801-810.
37. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. *BJU Int*. 2004;93(3):303-310.
38. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. *Urology*. 2003;62(2):237-242.
39. Coupland CAC, Hill T, Denning T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. *JAMA Intern Med*. 2019;179(8):1084-1093.
40. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol*. 2013;189(6):2186-2193.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Mirabegron is approved by the United States Food and Drug Administration for the treatment of overactive bladder (Myrbetriq, Astellas Pharma). Investigators should consult applicable regulatory authorities before any research application outside the approved indication.